La chaîne d'options affiche les données clés des options sur actions de Spectral AI à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Spectral AI..

Spectral AI (NASDAQ:MDAI) Stock, Chaîne d'Options

Spectral AI

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Spectral AI Inc

B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $127 to $122.

News

Price Target

Analyst Ratings

LNTH

B. Riley Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $122

WIIM

MNSO

MINISO Group Holding shares are trading lower following a Q2 sales miss.

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says The Answer To What "Transitory" Means This Time Around Is Whether The Tariffs Apply To Intermediate Goods, Stoke Retaliation, And Other Factors; Still Believe The Economy Is Resilient And If There Is Progress On Inflation Rates Will Be Lower In 12 To 18 Months; When There Is Uncertainty It Is A Time To Get As Much Data As Possible

A record number of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) vehicles have been traded this month, following protests against CEO Elon Musk&#8217;s role with the Donald Trump administration and the Department of Government Efficiency (DOGE), as per data from Edmunds.
What Happened: Tesla cars from model year 2017 or newer accounted for 1.4% of all the vehicles traded in until March 15, a significant increase from 0.4% in March last year, reported Reuters.
Analysts at Edmunds predict that this share could grow through the second half of the month.
Activists across the U.S. have staged Tesla Takedown demonstrations over Musk&#8217;s role in cuts to the federal workforce and cancellation of contracts that fund global humanitarian programs.
See Also:<a href="https://www.benzinga.com/25/03/44394560/elon-musks-tesla-targeted-with-arson-attacks-in-las-vegas-kansas-city-report"> Elon Musk&#8217;s Tesla Targeted With Arson Attacks In Las Vegas, Kansas City: Report</a>
This has led to a surge in Tesla trade-ins, with social media posts showing Tesla owners giving up their vehicles in displays of anger toward Musk.
&#8220;Brand loyalty is becoming a bigger question mark as factors such as Elon Musk&#8217;s increasing public involvement in government&#8230;leave some longtime owners feeling disconnected from the brand,&#8221; said Jessica Caldwell, Edmunds&#8217; head of insights.
Anger against the brand has escalated to the point of Tesla vehicles being set on fire and damage to the company&#8217;s showrooms and charging stations. Tesla&#8217;s stock has nearly halved from its January peak.
Why It Matters: This surge in trade-ins comes amid a series of setbacks for Tesla. There has been a significant<a href="https://www.benzinga.com/news/global/25/03/44128646/tesla-sales-drop-in-europe-in-february-some-countries-down-over-40-is-musks-political-push-hurting-ev-company"> drop</a> in Tesla sales in Europe, with some countries experiencing a decline of over 40%.
Furthermore, the company's Cybertruck is also<a href="https://www.benzinga.com/markets/equities/25/03/44429500/teslas-cybertruck-sales-at-just-47k-is-really-bad-for-250k-target-says-ross-gerber-amid-recall-troubles"> struggling</a>, with figures significantly below company projections. This was followed by a<a href="https://www.benzinga.com/markets/equities/25/03/44414187/elon-musks-tesla-recalls-over-46000-cybertrucks-due-to-safety-concerns"> recall</a> affecting 46,096 Cybertruck vehicles due to safety concerns.
Adding to the company&#8217;s woes, insurance premiums for Tesla vehicles are at risk of an<a href="https://www.benzinga.com/markets/equities/25/03/44432174/tesla-owners-might-have-to-pay-more-for-insurance-amid-a-surge-in-attacks-on-elon-musk-led-ev-giants-vehicles-expert"> increase</a> due to a surge in vandalism against the company&#8217;s vehicles, fuelled by resentment towards Musk over his role with the Trump administration.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44432174/tesla-owners-might-have-to-pay-more-for-insurance-amid-a-surge-in-attacks-on-elon-musk-led-ev-giants-vehicles-expert">Tesla Owners Might Have To Pay More For Insurance Amid A Surge In Attacks On Elon Musk-Led EV Giant&#8217;s Vehicles: Expert</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Markets

Tech

TSLA

Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism

Leerink Partners analyst Andrew Berens downgrades Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) from Outperform to Market Perform and lowers the price target from $9 to $1.

Downgrades

ELEV

Leerink Partners Downgrades Elevation Oncology to Market Perform, Lowers Price Target to $1

Planet Labs PBC&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) shares are trading lower premarket on Friday.
On Thursday, the company reported fourth-quarter adjusted losses of 8 cents per share, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44424832/planet-reports-financial-results-for-fourth-quarter-and-full-fiscal-year-2025" rel="noreferrer noopener">missing the consensus of 2 cents</a>.
Revenue of&nbsp;$61.6&nbsp;million, up 5% year over year, missed <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of $61.87 million</a>.
Percent of Recurring Annual Contract Value (ACV) for the&nbsp;fourth quarter&nbsp;stood at 97% and End of Period (EoP) Customer Count was 976.
As of January 31, 2025, backlog stood at $498.5 million. Non-GAAP gross margin was 65%, higher than 58%&nbsp;in the&nbsp;prior year quarter.
The company reported adjusted EBITDA profit of $2.4 million compared to a loss of $9.8 million in the fourth quarter of fiscal year 2024. This is the first quarter of adjusted EBITDA profitability in the company&#8217;s history.
The company ended the year with cash, cash equivalents and short-term investments of $222.1 million.
Will Marshall, Planet&#8217;s CEO, said, &#8220;We took a major step forward in the satellite services market and signed a $230 million contract with our long-term partner in Japan, JSAT. We launched over 70 satellites, including our first Tanager hyperspectral satellite and our second Pelican high resolution satellite, both of which are performing well in orbit.&#8221;
&#8220;Looking ahead, we are focused on driving growth in our core markets with solutions, and see a clear path to at least double our revenue growth rate in FY&#8217;27 compared to FY&#8217;26, supported by the significant increase in our backlog during Q4.&#8221;
Outlook:&nbsp;Planet Labs expects&nbsp;revenue in a range of&nbsp;$61 million&nbsp;to&nbsp;$63 million (vs. consensus of $64.7 million) for first-quarter FY26 and $260 million to $280 million&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(vs. estimate of $274.7 million) for FY26</a>.
The company sees adjusted EBITDA loss of around $3 million to $2 million for the first quarter and $13 million &#8211; $7 million for FY26.
In a separate release, the company disclosed that it released first light images from its Pelican-2 satellite of the Port of Laem Chabang in Eastern Thailand, which is the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44424963/planet-labs-pbc-releases-images-from-pelican-2" rel="noreferrer noopener">primary deep sea port in Thailand</a>.
Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Future Security ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITE#NYSE">FITE</a>) and&nbsp;Procure Space ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFO#NASDAQ">UFO</a>).
Price Action: PL shares are down 11.8% at $3.74 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/01/43298965/planet-labs-gains-on-multi-year-deal-with-european-space-agency" target="_blank" rel="noreferrer noopener">Planet Labs Gains On Multi-Year Deal With European Space Agency</a></li>
</ul>
Photo by rafapress via Shutterstock.

Earnings

Guidance

Small Cap

Movers

FITE

Planet Labs Stock Drops After Q4 Miss, Moderate Q1 & FY26 Guidance: Details

B. Riley Securities analyst Nick Giles initiates coverage on United States Antimony (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#AMEX">UAMY</a>) with a Buy rating and announces Price Target of $3.

Initiation

UAMY

B. Riley Securities Initiates Coverage On United States Antimony with Buy Rating, Announces Price Target of $3

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release its first-quarter financial results after the closing bell on Monday, March 24.
Analysts expect the company to report quarterly earnings at $1.58 per share, down from $1.76 per share in the year-ago period. KB Home projects quarterly revenue of $1.50 billion, compared to $1.47 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 10, Wells Fargo analyst Sam Reid maintained KB Home with an Underweight rating and lowered the price target from $65 to $63.
With the recent buzz around KB Home, some investors may be eyeing potential gains from the company's dividends too. At the moment, KB Home offers an annual dividend yield of 1.63%, which is a quarterly dividend amount of 25 cents per share ($1.00 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $367,620 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $73,524 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
KBH Price Action: Shares of KB Home fell 0.4% to close at $61.27 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/03/44414749/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-march">Top 2 Defensive Stocks That May Keep You Up At Night In March</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Trading Ideas

How To Earn $500 A Month From KB Home Stock Ahead Of Q1 Earnings

Fed's Goolsbee Says Before Judging How Monetary Policy Reacts To Tariffs, Fed Needs To Know How Long The Tariffs Last, Possible Retaliation, Pass Through To Consumers; Imports Are Only 11% Of GDP, So One Time Tariffs That Are Not Followed By Retaliation Are More Likely To Be Transitory; The Bigger They Are And The More Like Supply Shocks They Are The Harder It Will Be For The Fed To Look Through Them

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $15 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target

Truist Securities analyst Brian Foran maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Hold and lowers the price target from $77 to $65.

Truist Securities Maintains Hold on Synchrony Financial, Lowers Price Target to $65

GNLN

Greenlane FY24 EPS ($13.32) Down From ($8.16) YoY; Revenue $13.275M Down From $65.373M YoY.

Truist Securities analyst Brian Foran maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Hold and lowers the price target from $26 to $24.

Truist Securities Maintains Hold on Regions Finl, Lowers Price Target to $24

JP Morgan analyst Cory Carpenter reinstates IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) with a Overweight and announces $60 price target.

JP Morgan Reinstates Overweight on IAC, Announces $60 Price Target

Xcel Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XELB#NASDAQ">XELB</a>) ("Xcel Brands" or the "Company"), a media and consumer products company with significant expertise in livestream shopping and social commerce, today announced that it will effect a 1-for-10 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock par value $0.001 per share (the "Common Stock"), effective with the opening of trading on March 25, 2025.
Xcel Brands' Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "XELB". The new CUSIP number for the Common Stock following the Reverse Stock Split will be 98400M200.

Stock Split

XELB

Xcel Brands Announces 1-For-10 Reverse Stock Split, Effective March 25, 2025

Fed's Goolsbee Says Unemployment And Inflation Do Reflect Progress Towards The Dual Mandate

Truist Securities analyst Brian Foran maintains KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) with a Hold and lowers the price target from $19 to $18.

Truist Securities Maintains Hold on KeyCorp, Lowers Price Target to $18

Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers,&nbsp;today announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company's management will be presenting at the upcoming Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer 2025 Conference being held March 27th-29th, 2025 at The Roosevelt New Orleans Hotel in New Orleans, LA.
The newly completed strategic plan builds upon Silexion's recent promising preclinical data and is designed to maximize SIL-204's potential across multiple delivery approaches to address the challenges of KRAS-driven cancers. The Company plans to report further details on the expanded plan alongside its presentation at the conference.
A company presentation will take place during the conference's Innovation track on Friday, March 28th at 1:00pm. During this session, Silexion will present its strategic vision alongside recently reported preclinical findings from its SIL-204 program.

Biotech

General

SLXN

Silexion Announces Completion Of SIL204 Development Plan For KRAS Cancers; Presentation Scheduled At NeauxCancer 2025 Conference In New Orleans

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly sales of $2.800 million which missed the analyst consensus estimate of $3.020 million by 7.28 percent. This is a 7.50 percent decrease over sales of $3.027 million the same period last year.

Earnings Misses

AXDX

Accelerate Diagnostics Q4 Sales $2.800M Miss $3.020M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) with a Buy and maintains $10 price target.

LGVN

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

Press Releases

Spectral AI Provides Instructions for Retail Investors on Exercising Publicly-Traded Warrants

Spectral AI Provides Update to Investors

Spectral AI Completes Pediatric Enrollment in Emergency Departments for U.S. Burn Pivotal Study

Spectral AI Completes Data Analysis for U.S. Burn Pivotal Study

Opinion

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

Financing

Spectral AI Strengthens Financial Position Ahead of FDA Submission

CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

Spectral AI Completes Three Device Installations in Australia

Health Care

Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System

IPOs

Spectral AI Announces Public Filing of Registration Statement for Proposed Initial Public Offering of Spectral IP

ABSI

AVAI

GEHC

MDAI

MDAIW

TREN

HC Wainwright & Co.

Northland Capital Markets

BTIG

Screenshot 2024-06-04 at 5.43.27 PM

Interview

Revolutionizing Wound Care With Spectral AI - See How This AI Company Is Changing Critical Diagnostics

Comments

Spectral AI

Spectral AI (MDAI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL